Economic evaluation of enoxaparin sodium versus heparin in unstable angina: A French sub-study of the ESSENCE trial

PharmacoEconomics

Volumn 18, Issue 1, 2000, Pages 83-89

  Detournay, Bruno ^a   Huet, Xavier ^b   Fagnani, François ^a   Montalescot, Gilles ^c  

^a CEMKA EVAL   (France)

^b Laboratoires Rhone Poulenc Rorer S   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; HEPARIN DERIVATIVE;

ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST MINIMIZATION ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG COST; FRANCE; HEART INFARCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 0033941443     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200018010-00009     Document Type: Article

References (17)

1. 1. Theroux P, Quimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105-11
2. 2. Wallentin L, RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827-30
3. 3. Braunwald E, Jones RH, Mark DB, et al. Diagnosing and managing unstable angina. Agency for Health Care Policy and Research. Circulation 1994; 90 (1): 613-22
4. 4. Cairns JA, Lewis HD, Meade TW, et al. Antithrombotic agents in coronary artery disease. Chest 1995; 108: 380-400
5. 5. Hirsch J. Low-molecular-weight heparin: a review of the results of recent studies on the treatment of venous thromboembolism and unstable angina. Circulation 1998; 98: 1575-82
6. 6. Cohen M, Demers C, Gurkinkel EP, the ESSENCE Study Group, et al. A comparison of low-molecular weight heparin with unfractioned heparin for unstable coronary artery disease. N Engl J Med 1997; 337: 447-52
7. 7. Mark DB, Cowper PA, Berkowitz S, et al. Economic assessment of low molecular weight heparin (enoxaparin) versus unfractionned heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Circulation 1998; 97: 1702-7
8. 8. Unger F. European survey on cardiac interventions, open heart surgery, PTCA, and cardiac catheterisation 1993. Report of the Institute for Cardiac Survey of the European Academy of Sciences and Arts. Ann Eur Acad Sci Arts 1994; 8: 1-154
9. 9. Van den Brand M, the European Angioplasty Survey Group. Utilization of coronary angioplasty and cost of angioplasty disposables in 14 western European countries. Eur Heart J 1993; 14: 391-7
10. 10. Röthlisberger C, Meier B, the Working Group on Coronary Circulation of the European Society of Cardiology. Coronary interventions in Europe 1992. Eur Heart J 1995; 16: 922-9
11. 11. Selby JV, Fireman BH, Lundstrom RJ, et al. Variation among hospitals in coronary angiography practices and outcomes after myocardial infarction in a large health maintenance organization. N Engl J Med 1996; 335 (25): 1888-96
12. 12. Fox KAA, Bosanquet N. Assessing the UK cost implications of the use of low molecular weight heparin in unstable coronary artery disease. Br J Cardiol 1998; 5: 92-105
13. 13. Balen RM, Marra CA, Zed PJ, et al. Cost-effectiveness analysis of enoxaparin versus unfractionated heparin for acute conronary syndromes: a Canadian hospital perspective. Pharmacoeconomics 1999; 16 (5 Pt 2): 533-42
14. 14. Aden G. Fertigspritzen versus Ampullen: ein Anwendungsvergleich. Krankenhauspharmazie 1992; 5: 3-7
15. 15. Fabregas X, Garcia B, Jimenez I. Prefilled syringes: a valuable addition to the pharmacy. Int Pharm J 1996; 10: 138-9
16. 16. Cohen M, Bigonzi F, Le Louer V, the ESSENCE Group, et al. One year follow-up of the ESSENCE trial (enoxaparin versus heparin in unstable angina and non-Q-Wave myocardial infarction) [abstract]. J Am Coll Card 1998; 31 Suppl. A: 820-2
17. 17. Klein W, Buchwald A, Hillis SE, the FRIC investigators et al. Comparison of low molecular weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: fragmin in unstable coronary artery disease study (FRIC). Circulation 1997; 96: 61-8